|
Apr 24, 2018
|
Catalyst Pharmaceuticals Introduces New Corporate Website
|
|
|
Apr 19, 2018
|
Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis
|
|
|
Mar 29, 2018
|
Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla. , March 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its
|
|
|
Mar 14, 2018
|
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
--Firdapse ® NDA to be Resubmitted Before the End of this Quarter --Significant Progress with MuSK-MG Regulatory and Clinical Program -- $84M Year-End Cash and Investments --Company to Host Quarterly Conference Call at 5:00 pm ET Today CORAL GABLES, Fla.
|
|
|
Mar 12, 2018
|
Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast
CORAL GABLES, Fla. , March 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that
|
|
|
Mar 08, 2018
|
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018
CORAL GABLES, Fla. , March 08, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that
|
|
|
Feb 28, 2018
|
Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018
CORAL GABLES, Fla. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the
|
|
|
Feb 12, 2018
|
Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®
Positive meeting with the FDA about the resubmission of an NDA for Firdapse Resubmission of NDA for Firdapse on schedule for end of the first quarter CORAL GABLES, Fla. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on
|
|
|
Feb 07, 2018
|
Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
CORAL GABLES, Fla. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
